These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1364704)

  • 1. [One year experience of levonorgestrel-releasing intrauterine device].
    Lähteenmäki P; Shain RN; Ratsula K; Toivonen J; Holden AE; Rosenthal M; Luukkainen T
    Duodecim; 1991; 107(1):26-31. PubMed ID: 1364704
    [No Abstract]   [Full Text] [Related]  

  • 2. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer.
    Dinger J; Bardenheuer K; Minh TD
    Contraception; 2011 Mar; 83(3):211-7. PubMed ID: 21310281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
    Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
    Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of menstrual blood loss in Belgian users of the frameless copper-releasing IUD with copper surface area of 200 mm2 and users of a copper-levonorgestrel-releasing intrauterine system.
    Wildemeersch D; Rowe PJ
    Contraception; 2004 Aug; 70(2):169-72. PubMed ID: 15288224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levonorgestrel-releasing intrauterine device and uterine perforations.
    Prescrire Int; 2007 Dec; 16(92):248-9. PubMed ID: 18092420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC).
    van Vliet HA; Tchaikovski SN; Rosendaal FR; Rosing J; Helmerhorst FM
    Thromb Haemost; 2009 Apr; 101(4):691-5. PubMed ID: 19350113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of menstrual blood loss in Brazilian users of the frameless copper-releasing IUD with copper surface area of 330 mm2 and the frameless levonorgestrel-releasing intrauterine system.
    Andrade AT; Souza JP; Andrade GN; Rowe PJ; Wildemeersch D
    Contraception; 2004 Aug; 70(2):173-7. PubMed ID: 15288225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levonorgestrel-releasing intra-uterine systems (LNG-IUS) and breast cancer.
    Neven P; Amant F; Poppe W; Van den Broecke R
    Fertil Steril; 2009 Apr; 91(4):e5; author reply e6. PubMed ID: 19249759
    [No Abstract]   [Full Text] [Related]  

  • 9. [Abdominal migration of a levonorgestrel-releasing intrauterine device. Case report and review of the literature].
    Pont M; Lantheaume S
    J Gynecol Obstet Biol Reprod (Paris); 2009 Apr; 38(2):179-81. PubMed ID: 19303222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development.
    Shaamash AH; Sayed GH; Hussien MM; Shaaban MM
    Contraception; 2005 Nov; 72(5):346-51. PubMed ID: 16246660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Benefits of a levonorgestrel-releasing intrauterine device].
    Brun JL; Randriambelomanana J; Quiboeuf E; Dallay D
    J Gynecol Obstet Biol Reprod (Paris); 2009 May; 38 Spec No 3():F89-92. PubMed ID: 19736664
    [No Abstract]   [Full Text] [Related]  

  • 12. Intrauterine devices and adolescents.
    Gold MA; Johnson LM
    Curr Opin Obstet Gynecol; 2008 Oct; 20(5):464-9. PubMed ID: 18797269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis.
    de Sá Rosa e Silva AC; Rosa e Silva JC; Nogueira AA; Petta CA; Abrão MS; Ferriani RA
    Fertil Steril; 2006 Sep; 86(3):742-4. PubMed ID: 16784745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subject and clinician experience with the levonorgestrel-releasing intrauterine system.
    Jensen JT; Nelson AL; Costales AC
    Contraception; 2008 Jan; 77(1):22-9. PubMed ID: 18082662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levonorgestrel-releasing intrauterine system and new-onset acne.
    Ilse JR; Greenberg HL; Bennett DD
    Cutis; 2008 Aug; 82(2):158. PubMed ID: 18792549
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects of levonorgestrel-releasing intrauterine system on serum lipids and hepatic function].
    He SM
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1321-2, 1324. PubMed ID: 16234121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Levonorgestrel releasing intrauterine spiral--contraception and therapeutic indications].
    Kunz J
    Praxis (Bern 1994); 2001 Mar; 90(11):442-52. PubMed ID: 11293937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expulsion rate among users of two models of intrauterine devices (IUD), the Multiload 375 and the levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena).
    Petta CA; Faundes D; Bahamondes L
    Eur J Obstet Gynecol Reprod Biol; 2009 Mar; 143(1):64; author reply 64-5. PubMed ID: 19150168
    [No Abstract]   [Full Text] [Related]  

  • 19. Levonorgestrel-releasing intrauterine system for menstrual dysfunction: patient satisfaction in the district general hospital setting.
    Macnab JL; Lowles IE
    J Obstet Gynaecol; 2002 Jul; 22(4):402-5. PubMed ID: 12521465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levonorgestrel intrauterine device: new preparation. An alternative.
    Prescrire Int; 1999 Dec; 8(44):175-7. PubMed ID: 11503815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.